Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC

September 14th 2024

Treatment with belrestotug plus dostarlimab yielded a clinically meaningful improvement in ORR vs dostarlimab monotherapy in unresectable PD-L1–high NSCLC.

DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets

September 13th 2024

T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.

Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC

September 13th 2024

BMS-986012 plus nivolumab and chemotherapy provided a modest PFS benefit but signals of OS improvement in extensive-stage small cell lung cancer.

Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma

September 13th 2024

Breelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.

Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC

September 13th 2024

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status

September 10th 2024

Rilvegostomig induced responses with acceptable tolerability in patients with checkpoint inhibitor-naive, metastatic NSCLC.

Global Survey Examines Barriers to Optimal Lung Cancer Biomarker Testing

September 8th 2024

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes

September 7th 2024

Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.

Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma

September 7th 2024

Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology

September 6th 2024

The NCCN Clinical Practice Guidelines in Oncology now list denileukin diftitox as an appropriate option for patients with cutaneous T-cell lymphoma.

FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL

September 6th 2024

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.

Talazoparib Plus Pacritinib Aims to Improve the Limitations of Second-Line Therapy in MPNs

September 5th 2024

Peter Abdelmessieh, DO, MSC, discusses the phase 1 trial testing the combination of talazoparib and pacritinib in myeloproliferative neoplasms.

FDA Awards Orphan Drug Designation to ABD-147 for Neuroendocrine Carcinoma

September 5th 2024

ABD-147 has received orphan drug designation from the FDA for use in patients with neuroendocrine carcinoma.

Pyrotinib Plus Metronomic Vinorelbine Is Active in HER2+ Advanced Breast Cancer After Trastuzumab

September 5th 2024

Pyrotinib paired with metronomic vinorelbine was safe and displayed efficacy in HER2-positive advanced breast cancer after prior trastuzumab.

OncLive’s August Roundup of Key FDA Approvals in Oncology

September 4th 2024

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

FDA Green Lights Companion Diagnostics for Olaparib Plus Abiraterone Acetate in BRCA+ mCRPC

September 3rd 2024

The FDA approved companion diagnostics for olaparib plus abiraterone in metastatic castration-resistant prostate cancer.

Mirdametinib Induces Significant Responses in NF1-Associated Plexiform Neurofibroma

September 3rd 2024

Mirdametinib showed a statistically significant ORR by BICR, with deep and durable tumor volume reductions in adults and children with NF1-PN.

MT-302 Under Investigation in Advanced or Metastatic Epithelial Tumors

September 3rd 2024

Charlotte Lemech, MBBS, discusses the mechanism of action of MT-302, as well as the aims of the MYE Symphony trial and its potential future implications.

Encorafenib/Binimetinib Combo Approved in Europe for BRAF V600E+ NSCLC

August 30th 2024

Encorafenib plus binimetinib has won approval from the European Commission for use in patients with BRAF V600E-mutated, advanced non–small lung cancer.

Is the Current Framework of Academic Oncology Failing Community Providers?

August 30th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.